Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …

The ongoing massive vaccination and the development of effective intervention offer the
long-awaited hope to end the global rage of the COVID-19 pandemic. However, the rapidly …

The accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of
neutralizing antibody-based therapeutics is a concern with potentially severe implications for …

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …

Since the worldwide emergence of the COVID-19 outbreak, there have been international
concerns about the possible viral evolution into variants with underlying mutations that may …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …